IT IS NOW generally acknowledged that estrogen deprivation is an integral part of the endocrine treatment strategy in patients with breast cancer. In postmenopausal women, the main source for estrogens comes from the aromatization of adrenal androgens. Therefore, inhibitors of the aromatase enzyme system have become of interest during recent years; they are used both to lower systemic estrogen levels and, perhaps more importantly, to inhibit intracellular conversion of androgens to estrogens by the tumor cell aromatase. 1 Aminoglutethimide has gained an established place in antiestrogenic treatment by inhibition of aromatase. 2 -4 However, this drug has been demonstrated to inhibit also several steps in adrenal steroid biosynthesis other than the aromatase 4 and to be associated with a substantial number and degree of side effects, thus warranting the search for equally efficacious but less toxic alternatives.
Among several selective inhibitors of aromatase, 4-hydroxyandrostenedione proved promising both in vitro 5 and in the first clinical study.6-9 Its mechanism of action has been shown to be a competitive inhibition of the aromatase enzyme system. It does not interfere with other adrenal enzymes, notably the cortisol or aldosterone synthesis. 5 Therefore, no cortisol substitution is needed. We report here on our experience using 4-hydroxyandrostenedione in the treatment of postmenopausal breast cancer patients.
PATIENTS AND METHODS

Patients
Between October 1986 and March 1988, 91 patients with advanced breast cancer entered a phase II study with 4-hydroxyandrostenedione. There were 26, 49, and 16 patients included by the three participating centers. Drug dosage was as follows: 2 x 250 mg intramuscularly (IM) every 2 weeks for the first 6 weeks and 250 mg IM every 2 weeks, thereafter. All patients were either postmenopausal or surgically oophorectomized (9 to 96 months before the present treatment), and most had previously received hormonal treatment and/or chemotherapy. Informed consent was obtained from each patient. Treatment with 4-hydroxyandrostenedione was initiated only in patients who were at least 2 weeks off any tumor-specific treatment and exhibited unequivocal evidence of progressive metastatic disease.
Except for irradiation of local bone metastases, no concomitant tumor-specific treatment was allowed. In cases requiring irradiation, local responses were excluded from evaluation of the overall response.
Response Criteria
Responses were assessed according to the International Union Against Cancer guidelines.'o Partial remission (PR) was defined as either a 50% decrease in the sum of products of all measurable lesions or the recalcification of lytic lesions as determined by x-ray, developing in the absence of new lesions. Stable disease (no change; [NC]) was defined as patients with metastatic lesions who did not show disease progression or new lesions and who also had relief of bone pain (if applicable) for at least 2 months. Progressive disease was defined as the development of new lesions or an increase in old lesions. Time to treatment failure was defined by the interval between the initation of treatment and the first documentation of disease progression.
Clinical Evaluation and Hormone Assays
Case histories and physical examinations (including blood pressure, complete blood counts, and serum electrolytes, as well as liver and renal function parameters) were performed weekly for the first 6 weeks of treatment and monthly thereafter. All patients were followed until disease progression. Using a commercially available radioimmunoassay (Baxter, Federal Republic of Germany), serum levels of estradiol were determined after ether extraction of serum samples. The interassay coefficient of variation for an estradiol value of 21 pg/mL was 25%.
Statistical Analysis
Statistical evaluation of the results was performed by using the Poisson distribution for calculating the 95% confidence interval," the standard life-table analysis 2 for estimating time to progression rates, and the Friedman two-way analysis of variance followed by Wilcoxon and Wilcox multiple comparisons for determination of the significance in differences. Significance for the differences in serum estradiol values was determined only for a 15 samples per point (Fig 1) .
RESULTS
The major clinical characteristics of the 91 patients who entered this trial are outlined in Table 1 . Ninety patients were assessable for toxicity since one patient was lost to follow-up after the first injection of the drug. Eighty-six patients (95%) met the criteria for response evaluation. In the remaining five patients, response to 4-hydroxyandrostenedione was not assessable because of (1) poor compliance in one patient, and (2) were included in the analysis and considered as having progressive disease. The mean age of the patients was 59 years and the mean Karnofsky performance status was 877 80%. All patients were in artificial (oophorectomized) or natural menopause. Oophorectomy had been performed 9 to 96 months (mean, 43) before study entry.
In two of three patients, the estrogen receptor status of primary or metastatic tumor tissue was positive. Most patients had been pretreated either with hormones and/or with chemotherapy.
There was a notable predominance of bone metastases, and 33% of the patients had visceral lesions. The number of metastatic lesions referred to the main localizations at regional, bone, and visceral sites. Thus, the majority of patients had one or two organs involved. Table 2 shows the overall results, including the 95% confidence intervals, for 4-hydroxyandrostenedione of the 91 patients. Objective remissions (complete [CRs] and PRs) on treatment for 3 + to 27 + months were observed in 23% of the patients and stabilizations of previously progressive disease with a median duration on treatment of 8 months (range, 3 to 22+) were induced in 29% of the patients. Forty-eight percent of the patients failed to respond to 4-hydroxyandrostenedione. Figure 2 illustrates the interval between initiation of treatment and documentation of disease progression (time to treatment failure) for patients experiencing objective remissions or disease stabilization with 4-hydroxyandrostenedione as compared with patients showing progressive disease.
Response to Therapy
In Table 3 , 4-hydroxyandrostenedione treatment results are related to estrogen receptor status and disease-free interval between mastectomy and first occurrence of metastases. It can be seen that patients with unknown receptor status did not respond less than those having positive estrogen receptors (> 10 fmol/mg of cytosol Months protein). In addition, one patient with a negative receptor status responded to 4-hydroxyandrostenedione. There was no obvious difference either in response rates or in treatment failures of patients with short (< 2 years) or long diseasefree intervals. Table 4 shows the treatment results related to sites of metastases and the number of major metastatic localizations (ie, regional, bone, visceral). There was no significant difference, although patients with visceral metastases and those with all three localizations involved obviously had the highest risk for treatment failure. In Table 5 , results are related to prior tamoxifen treatment in 55 patients whose previous responses to the antiestrogen could be assessed. As expected, patients having responded to prior antiestrogenic treatment experienced the best treatment results with 4-hydroxyandrostenedione. However, four of 27 patients with prior disease stabilization and one of seven patients in I patients withl aavancea 3 0 breast cancer according to treatment efficacy.
progressing during tamoxifen treatment responded to 4-hydroxyandrostenedione treatment with objective remissions. Table 6 shows that only 11% of all patients had systemic and only 8% of the 91 patients experienced local side effects related to 4-hydroxyandrostenedione treatment. The toxicities seen were mostly mild and transient. Only three patients discontinued the treatment due to subjectively intolerable side effects. Despite the known androgenic effect of 4-hydroxyandrostenedione (eg, in vitro and in experimental animal systems), no androgenic side effects were encountered.
Side Effects
Hormone Studies
Serum estradiol levels decreased significantly (P < .05) after 2 weeks of treatment and remained suppressed throughout the observation period (Fig 2) . The apparent increase after 16 weeks of treatment was only of a transient nature. After 3 months, no further statistical evaluation of significance was performed due to the low sample numbers (see Patients and Methods). Random controls of serum cortisol levels by a routine assay did not exhibit any significant alterations (data not shown).
4-HYDROXYANDROSTENEDIONE IN BREAST CANCER
Other Blood Examinations
No alterations in blood chemistry were observed in total blood cell counts, serum electrolytes, or liver and kidney function parameters (data not shown).
DISCUSSION
The present study has shown that 4-hydroxyandrostenedione is effective in treating postmenopausal patients with advanced breast cancer. The 23% objective remission rate observed in 91 patients compares favorably with the previously reported 27% response rate achieved by treating 52 patients with 500 mg 4-hydroxyandrostenedione IM every other week continuously.' Responses to 4-hydroxyandrostenedione may be Comparing different doses and routes of administration, 250 mg IM every other week or 500 mg orally daily may be sufficient to suppress estradiol levels constantly in such patients.8 Therefore, treatment failure is dependent on lack of hormone sensitivity of the malignant disease and is not influenced by suboptimum dosage. 8 Estrogen receptor status does not necessarily predict response to aromatase inhibitors. Patients with unknown and even negative receptors may benefit from this treatment as evidenced by the present study. This is supported by other studies 6 ' 7 and the observation that the inhibition of tumor cell aromatase may be more important for the efficacy of the treatment than that of the peripheral (fat tissue) aromatase.' In line with the low predictive value of estrogen receptor positivity, no difference in response was seen with regard to short or long disease-free intervals.
Coombes et al a better response of bone metastases. However, this was not apparent in the present study and thus, not as obvious as with aminoglutethimide. [2] [3] [4] In accordance with the findings of Coombes et al, 6 ' 7 we observed a close relationship between the success of previous hormone treatment and the response to 4-hydroxyandrostenedione.
Side effects in 17% of the patients were mostly mild and tolerable. In three patients, however, treatment had to be discontinued, albeit due to medical reasons in one patient only. This is supported by the experience of the English group 7 encountering mostly local reactions (including sterile abscesses) and having to stop treatment because of toxicity in 3% of the patients.
In this context, it should be noted that, dependent on dosage, 30% to 80% of patients on aminoglutethimide experienced side effects of sometimes substantial degree leading to discontinuation of the treatment in up to 10% of the patients. Thus, 4-hydroxyandrostenedione provides a less toxic means of aromatase inhibition for treatment of postmenopausal breast cancer. Moreover, there is no interference with other hormonal systems, eg, steroidogenesis, which appeared to be a drawback of aminoglutethimide treatment. 4 Also, there were no side effects on other organ systems (bone marrow, liver, kidney).
Thus, apart from local irritations and occasional allergic reactions, 4-hydroxyandrostenedione appears to be a manageable and clinically active aromatase inhibitor.
